A high bioavailability valsartan hydrochlorothiazide solid dispersion tablet and a preparation method and application thereof

CN121313576BActive Publication Date: 2026-09-15ZHEJIANG NUODE PHARM CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202511751647.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-11-26
Publication Date
2026-09-15
Estimated Expiration
2045-11-26

AI Technical Summary

Technical Problem

然而,这些常规技术方案仍存在明显的局限性,具体表现在以下两个方面:(1)单一载体材料的固有缺陷难以克服:当仅使用疏水性载体如EC时,虽能在一定程度上阻隔水分、提高制剂稳定性,但对药物溶解度的提升极为有限,难以实现生物利用度的显著突破

Benefits of technology

[0023] (1) This invention constructs a unique carrier network structure by combining HPMCAS and EC, which effectively inhibits the recrystallization of drug molecules and stabilizes them in an amorphous state. Based on this, the combined carrier, cosolvent, surfactant, and cyclodextrin produce a significant synergistic solubilizing effect: the cosolvent increases the solubility of the drug, the surfactant reduces the interfacial tension of the dissolution medium, and the cyclodextrin further facilitates dissolution by forming inclusion complexes with the drug. This multi-pathway synergistic effect overcomes the solubility bottleneck of valsartan and hydrochlorothiazide. Experimental data show that compared with conventional non-solid dispersion tablets, the tablets of this invention have a dissolution rate that is more than 30% higher at 45 min, and in vivo pharmacokinetic studies in animals show that their bioavailability is increased by more than 60%, fundamentally solving the problem of insufficient efficacy caused by low dissolution rate in the original formulation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121313576B_ABST
    Figure CN121313576B_ABST
Patent Text Reader

Abstract

The application discloses a high-bioavailability valsartan hydrochlorothiazide solid dispersion tablet and a preparation method and application thereof, raw materials of the tablet comprising valsartan, hydrochlorothiazide and a solid dispersion carrier, and the core lies in that the solid dispersion carrier is a compound of hydroxypropyl methyl cellulose acetate succinate and ethyl cellulose, and is used in cooperation with a cosolvent, a surfactant and a cyclodextrin. The application realizes significant improvement of the dissolution and bioavailability and reliable guarantee of long-term stability by carrier compounding and cooperation with excipients. Compared with conventional preparations, the tablet has a 30% or more increase in 45 min dissolution, a 60% or more increase in bioavailability, and no change in impurity level within 6 months of an accelerated test, and solves the technical problem that a single carrier system is difficult to balance dissolution and stability. In addition, the preparation process of the application is suitable for large-scale industrial production and has extremely high industrial transformation value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical formulation technology, specifically relating to a highly bioavailable valsartan-hydrochlorothiazide solid dispersion tablet, its preparation method, and its application. Background Technology

[0002] Hypertension is a common chronic disease and a major risk factor for cardiovascular and cerebrovascular diseases. Valsartan, an angiotensin II receptor antagonist, inhibits the activity of angiotensin II by specifically antagonizing AT1 receptors, thereby causing vasodilation and lowering blood pressure. Hydrochlorothiazide, a thiazide diuretic, increases the excretion of sodium, chloride ions, and water by affecting the reabsorption of electrolytes in the renal tubules, thus reducing blood volume. The combination of these two drugs is widely used clinically to treat patients whose blood pressure cannot be adequately controlled by a single drug, as it can synergistically enhance efficacy and reduce adverse reactions.

[0003] However, both valsartan and hydrochlorothiazide belong to Biopharmaceutics Class II drugs, characterized by low solubility and high permeability. This characteristic limits the in vivo absorption of their oral formulations due to dissolution rate, resulting in low bioavailability and consequently affecting clinical efficacy. To address this issue, solid dispersion technology is widely considered an effective strategy for improving the dissolution and bioavailability of poorly soluble drugs.

[0004] In existing technologies, various polymer carriers are used to prepare solid dispersions of valsartan and / or hydrochlorothiazide, such as povidone (PVP), hydroxypropyl methylcellulose (HPMC), ethyl cellulose (EC), and hydroxypropyl methylcellulose acetate succinate (HPMCAS). However, these conventional technical solutions still have obvious limitations, specifically in the following two aspects: (1) The inherent defects of a single carrier material are difficult to overcome: When only hydrophobic carriers such as EC are used, although they can block water and improve the stability of the formulation to a certain extent, the improvement in drug solubility is extremely limited, and it is difficult to achieve a significant breakthrough in bioavailability. Conversely, when only enteric or hydrophilic carriers such as HPMCCAS are used, although they can utilize their pH-dependent solubility characteristics to rapidly release the drug in the intestine and significantly improve the dissolution rate, the hydrophilic properties of the carrier itself or its sensitivity to water molecules can easily lead to recrystallization, phase separation, or chemical degradation of the drug during storage, resulting in poor long-term stability and a significant increase in related substances. This means that a single carrier system cannot simultaneously achieve the two core objectives of "high dissolution" and "high stability". (2) Performance bottleneck of traditional conventional preparations: Conventional tablets using non-solid dispersion technology (such as copovidone as a disintegrant in common formulations) have simple preparation processes, low costs, and acceptable short-term stability, but they cannot effectively change the dissolution behavior of the drug, resulting in low dissolution rate and degree, and the bioavailability cannot meet the clinical scenarios with higher requirements for drug efficacy.

[0005] Therefore, those skilled in the art have long faced a prominent technical contradiction: pursuing high dissolution and bioavailability often requires sacrificing the long-term stability of the formulation; while ensuring stability makes it difficult to achieve a leap in dissolution and bioavailability. Developing a novel formulation technology that can effectively resolve the above contradiction has become an urgent technical problem to be solved in this field. Summary of the Invention

[0006] To address the shortcomings of existing technologies, this invention provides a high-bioavailability valsartan-hydrochlorothiazide solid dispersion tablet, its preparation method, and its application. This solid dispersion system can systematically integrate the advantages of different carriers and synergistically enhance the effects of cosolvents, surfactants, and other excipients, thereby significantly improving drug dissolution and bioavailability while ensuring the long-term chemical stability and production feasibility of the formulation.

[0007] This invention is achieved through the following technical solution:

[0008] A highly bioavailable valsartan / hydrochlorothiazide solid dispersion tablet is composed of the following raw materials in parts by weight: 10-16 parts valsartan, 1-2 parts hydrochlorothiazide, 10-16 parts solid dispersion carrier, 3-5 parts solubilizer, 1-3 parts surfactant, and 4-6 parts cyclodextrin and its derivatives; wherein the solid dispersion carrier is a compound of hydroxypropyl methylcellulose acetate succinate and ethylcellulose, and the compound is used to synergistically improve the dissolution rate of valsartan and the chemical stability of the formulation.

[0009] Preferably, the mass ratio of hydroxypropyl methylcellulose acetate succinate to ethyl cellulose is (3~4):1.

[0010] Preferably, the co-solvent is at least one of polyethylene glycol 4000 and mannitol.

[0011] Preferably, the surfactant is at least one of Tween 80 and sodium dodecyl sulfate.

[0012] Preferably, the cyclodextrin and its derivatives are at least one of β-cyclodextrin and hydroxypropyl-β-cyclodextrin.

[0013] Preferably, the product also includes pharmaceutically acceptable excipients, said excipients including fillers and lubricants; said filler is microcrystalline cellulose and said lubricant is magnesium stearate.

[0014] The method for preparing the above-mentioned highly bioavailable valsartan / hydrochlorothiazide solid dispersion tablets includes the following steps:

[0015] Step 1) Weigh out the prescribed amounts of valsartan, hydrochlorothiazide, hydroxypropyl methylcellulose acetate succinate, and ethylcellulose, add them to an organic solvent, and stir in a water bath at 60-70°C until completely dissolved to form a drug-carrier solution.

[0016] Step 2) Add solubilizer, surfactant and cyclodextrin and its derivatives to the drug-carrier solution obtained in Step 1), and continue stirring for 30-40 min to form a homogeneous mixture;

[0017] Step 3) Spray dry the mixture obtained in step 2) and collect the solid dispersion powder;

[0018] Step 4) Add pharmaceutical excipients to the solid dispersion powder obtained in step 3), mix evenly, and then compress into tablets to obtain the final product.

[0019] Preferably, the organic solvent in step 1) is an ethanol-acetone mixed solvent.

[0020] Preferably, the inlet air temperature of the spray dryer in step 3) is 160~180℃ and the outlet air temperature is 80~90℃.

[0021] The above-mentioned tablets, or tablets prepared by the above-mentioned method, are used in the preparation of drugs for treating hypertension.

[0022] The beneficial effects of this invention are as follows:

[0023] (1) This invention constructs a unique carrier network structure by combining HPMCAS and EC, which effectively inhibits the recrystallization of drug molecules and stabilizes them in an amorphous state. Based on this, the combined carrier, cosolvent, surfactant, and cyclodextrin produce a significant synergistic solubilizing effect: the cosolvent increases the solubility of the drug, the surfactant reduces the interfacial tension of the dissolution medium, and the cyclodextrin further facilitates dissolution by forming inclusion complexes with the drug. This multi-pathway synergistic effect overcomes the solubility bottleneck of valsartan and hydrochlorothiazide. Experimental data show that compared with conventional non-solid dispersion tablets, the tablets of this invention have a dissolution rate that is more than 30% higher at 45 min, and in vivo pharmacokinetic studies in animals show that their bioavailability is increased by more than 60%, fundamentally solving the problem of insufficient efficacy caused by low dissolution rate in the original formulation.

[0024] (2) The innovative compounding strategy of this invention not only achieves high dissolution but also unexpectedly solves the industry problem of poor long-term stability of solid dispersions with single carriers. Specifically, the hydrophobic properties of EC effectively reduce the contact between the drug and moisture in the environment, while HPMCAS provides good stability in gastrointestinal fluids. The combination of these two components works synergistically at both physical and chemical levels, avoiding the insufficient drug dissolution when using EC alone and overcoming the drawbacks of easy crystallization and chemical impurity growth when using HPMCAS alone. Accelerated stability testing (40℃±2℃, relative humidity 75%±5%) showed that the impurity level of the tablets of this invention remained essentially unchanged compared to day 0 during a 6-month test, demonstrating excellent chemical stability comparable to conventional stable formulations. In contrast, the control formulation using a single carrier showed a total impurity increase to 3.5%~3.7% under the same conditions, fully demonstrating the synergistic advantage of the compounded carriers in stability of this invention.

[0025] (3) The spray drying process used in this invention has the characteristics of high production efficiency and easy scale-up. The solid dispersion powder has excellent flowability, which greatly facilitates subsequent mixing, filling and tableting operations, ensuring that the final tablet product has ideal content uniformity and low tablet weight variation. The entire production process is consistent and stable, and has extremely high industrial transformation value. Attached Figure Description

[0026] Figure 1 This is a comparison chart of the dissolution curves of the tablets prepared in Examples 1-3 and Comparative Examples 1-6 in the medium in Test Example 1;

[0027] Figure 2 The high-performance liquid chromatogram of the tablet prepared in Example 2 of Test Example 2 after being stored under long-term test conditions for 0 months;

[0028] Figure 3 The high-performance liquid chromatogram of the tablet prepared in Example 2 of Test Example 2 after being placed under long-term test conditions for 12 months;

[0029] Figure 4 The high-performance liquid chromatogram of the tablet prepared in Comparative Example 3 of Test Example 2 after being stored under accelerated test conditions for 6 months;

[0030] Figure 5 The high-performance liquid chromatogram of the valsartan + hydrochlorothiazide reference solution in test example 2 is shown. Detailed Implementation

[0031] The present invention will now be described in further detail with reference to the accompanying drawings and specific embodiments.

[0032] Unless otherwise specified, the technical means used in the following embodiments are all conventional means well known to those skilled in the art, and the experimental methods without specific conditions are all conventional methods in the art.

[0033] Unless otherwise specified, all materials and reagents used in the following examples are commercially available.

[0034] A highly bioavailable valsartan-hydrochlorothiazide solid dispersion tablet, wherein the core components of the solid dispersion (parts by weight) include: 10-16 parts valsartan, 1-2 parts hydrochlorothiazide, 10-16 parts solid dispersion carrier, 3-5 parts cosolvent, 1-3 parts surfactant, and 4-6 parts cyclodextrin and its derivatives.

[0035] The solid dispersion carrier is a compound of HPMCAS (8-12 parts) and EC (2-4 parts), which is used to synergistically improve the dissolution rate of valsartan and the chemical stability of the formulation.

[0036] The co-solvent is selected from at least one of polyethylene glycol 4000 and mannitol.

[0037] The surfactant is selected from at least one of Tween 80 and sodium dodecyl sulfate.

[0038] The cyclodextrin and its derivatives are selected from at least one of β-cyclodextrin or hydroxypropyl-β-cyclodextrin.

[0039] The specific steps of its preparation method are as follows:

[0040] (1) Weigh out the prescribed amounts of valsartan, hydrochlorothiazide, HPMCAS, and EC, add them to an appropriate amount of ethanol-acetone mixed solvent (volume ratio 1:1), and stir in a water bath at 60~70℃ until completely dissolved to form a drug-carrier solution.

[0041] (2) Add solubilizer, surfactant and cyclodextrin to the above solution and continue stirring for 30-40 min to form a uniform mixture.

[0042] (3) Spray dry the mixture (inlet air temperature 160~180℃, outlet air temperature 80~90℃) and collect the solid dispersion powder.

[0043] (4) Add pharmaceutical excipients such as microcrystalline cellulose (filler) and magnesium stearate (lubricant) to the solid dispersion powder, mix evenly, and then compress into tablets to obtain the product.

[0044] Example 1

[0045] A highly bioavailable valsartan-hydrochlorothiazide solid dispersion tablet, the core components of which (parts by weight) include: 10 parts valsartan, 1 part hydrochlorothiazide, 8 parts HPMCAS, 2 parts EC, 3 parts polyethylene glycol 4000, 1 part Tween 80, and 4 parts β-cyclodextrin.

[0046] The specific steps of its preparation method are as follows:

[0047] (1) Weigh out the prescribed amounts of valsartan, hydrochlorothiazide, HPMCAS, and EC, add them to an appropriate amount of ethanol-acetone mixed solvent (volume ratio 1:1), and stir in a water bath at 60~70℃ until completely dissolved to form a drug-carrier solution.

[0048] (2) Add solubilizer, surfactant and cyclodextrin to the above solution and continue stirring for 30-40 min to form a uniform mixture.

[0049] (3) Spray dry the mixture, set the inlet air temperature to 160°C and the outlet air temperature to 80°C, and collect the solid dispersion powder.

[0050] (4) Add 15 parts of microcrystalline cellulose and 0.5 parts of magnesium stearate to the solid dispersion powder, mix evenly and compress into tablets to obtain the product.

[0051] Example 2

[0052] A highly bioavailable valsartan-hydrochlorothiazide solid dispersion tablet, the core components of which (parts by weight) include: 12 parts valsartan, 1.5 parts hydrochlorothiazide, 9 parts HPMCAS, 3 parts EC, 4 parts mannitol, 2 parts sodium dodecyl sulfate, and 5 parts hydroxypropyl-β-cyclodextrin.

[0053] The preparation method is the same as in Example 1, except that the inlet air temperature of the spray drying is set to 170°C and the outlet air temperature is set to 85°C; 18 parts of microcrystalline cellulose and 0.6 parts of magnesium stearate are added during tableting.

[0054] Example 3

[0055] A highly bioavailable valsartan-hydrochlorothiazide solid dispersion tablet, the core components of which (parts by weight) include: 16 parts valsartan, 2 parts hydrochlorothiazide, 12 parts HPMCAS, 4 parts EC, 5 parts polyethylene glycol 4000, 3 parts Tween 80, and 6 parts β-cyclodextrin.

[0056] The preparation method is the same as in Example 1, except that the inlet air temperature is set to 180°C and the outlet air temperature is set to 90°C during spray drying; and 20 parts of microcrystalline cellulose and 0.8 parts of magnesium stearate are added during tableting.

[0057] Comparative Example 1 (Conventional formulation, non-solid dispersion process)

[0058] A method for preparing valsartan-hydrochlorothiazide tablets, comprising (parts by weight) 12 parts valsartan, 1.5 parts hydrochlorothiazide, 20 parts microcrystalline cellulose (filler), 10 parts lactose (filler), 5 parts hydroxypropyl cellulose (binder), and 1 part magnesium stearate (lubricant).

[0059] The preparation method (conventional wet granulation process) is as follows:

[0060] The drug and excipients were mixed, and a 5% aqueous solution of hydroxypropyl cellulose was added to prepare a soft mass. The mass was granulated by passing it through a 20-mesh sieve, dried at 60°C for 2 hours, and then compressed into tablets (as a reference preparation).

[0061] Comparative Example 2 (Single Dispersion Carrier: EC Only)

[0062] A method for preparing valsartan hydrochlorothiazide tablets, comprising (parts by weight) 12 parts valsartan, 1.5 parts hydrochlorothiazide, 12 parts EC (total amount of HPMCAS+EC replacing the compound carrier), 4 parts mannitol, 2 parts sodium dodecyl sulfate, and 5 parts hydroxypropyl-β-cyclodextrin.

[0063] The preparation method is the same as in Example 2, except that HPMCAS is removed and the amount of EC is increased to ensure that the total mass of the carrier is equivalent to that of the compound system.

[0064] Comparative Example 3 (Single Dispersion Carrier: HPMCAS Only)

[0065] A method for preparing valsartan-hydrochlorothiazide tablets, comprising (parts by weight) 12 parts valsartan, 1.5 parts hydrochlorothiazide, 12 parts HPMCAS (total HPMCAS+EC replacing the compound carrier), 4 parts mannitol, 2 parts sodium dodecyl sulfate, and 5 parts hydroxypropyl-β-cyclodextrin.

[0066] The preparation method is the same as in Example 2, except that EC is removed and the amount of HPMCAS is increased to ensure that the total mass of the carrier is equivalent to that of the compound system.

[0067] Comparative Example 4 (Acyclic Dextrin)

[0068] A method for preparing valsartan-hydrochlorothiazide tablets, comprising (parts by weight) 12 parts valsartan, 1.5 parts hydrochlorothiazide, 9 parts HPMCAS, 3 parts EC, 4 parts mannitol, and 2 parts sodium dodecyl sulfate.

[0069] The preparation method is the same as in Example 2, except that 5 parts of hydroxypropyl-β-cyclodextrin are removed.

[0070] Design objective: To verify the synergistic effect of cyclodextrin on drug dissolution and stability.

[0071] Comparative Example 5 (without surfactant)

[0072] A method for preparing valsartan hydrochlorothiazide tablets, comprising (parts by weight) 12 parts valsartan, 1.5 parts hydrochlorothiazide, 9 parts HPMCAS, 3 parts EC, 4 parts mannitol, and 5 parts hydroxypropyl-β-cyclodextrin.

[0073] The preparation method is the same as in Example 2, except that 2 parts of sodium dodecyl sulfate are removed.

[0074] Design objective: To verify the key role of surfactants in drug dissolution rate.

[0075] Comparative Example 6 (Acyclodextrin + No Surfactant)

[0076] A method for preparing valsartan-hydrochlorothiazide tablets, comprising (parts by weight) 12 parts valsartan, 1.5 parts hydrochlorothiazide, 9 parts HPMCAS, 3 parts EC, and 4 parts mannitol.

[0077] The preparation method is the same as in Example 2, except that 5 parts of hydroxypropyl-β-cyclodextrin and 2 parts of sodium dodecyl sulfate are removed.

[0078] Design objective: To verify the necessity and synergistic effect of "sharing" cyclodextrin and surfactant.

[0079] Test Example 1: Dissolution Test

[0080] 1. Experimental Design

[0081] Dissolution test was performed according to the 2025 edition of the Chinese Pharmacopoeia, Part IV (paddle method), using 900 mL of 0.1 mol / L hydrochloric acid solution as the dissolution medium and a rotation speed of 50 rpm. Sampling times were 5, 15, 30, 45, and 60 min. The samples tested were tablets prepared in Examples 1-3 and Comparative Examples 1-6.

[0082] 2. Experimental Data and Results

[0083] Table 1 Dissolution test results

[0084]

[0085] 3. Data Analysis

[0086] The dissolution test results are shown in Table 1 and Figure 1 As shown, the specific analysis is as follows:

[0087] Examples 1-3 (compound carrier + excipients): rapid dissolution within 5 min (dissolution amount 58.2%~62.3%), dissolution amount reached 79.5%~83.1% within 15 min, approached the plateau period (92.1%~94.5%) within 30 min, and the dissolution amount stabilized at 95.3%~97.8% within 45~60 min without fluctuation.

[0088] Comparative Example 1 (conventional formulation): Dissolution was slow throughout the process, reaching only 69.5% at 60 min, and did not reach the plateau phase.

[0089] Comparative Examples 2-3 (single carrier): The dissolution rate was between that of the examples and conventional formulations, with a dissolution rate of 83.0%~85.2% at 60 min, which was still lower than that of the examples.

[0090] Comparative Examples 4-6 (lacking excipients): Comparative Example 4 (without cyclodextrin) had a dissolution rate of 79.2% at 60 min, Comparative Example 5 (without surfactant) had a dissolution rate of 76.3% at 60 min, and Comparative Example 6 (without both) had a dissolution rate of 68.8% at 60 min (basically consistent with conventional formulations), with no plateau phase, demonstrating that the lack of excipients led to a significant decrease in dissolution capacity.

[0091] The experimental results of this test example show that the synergistic system of compound carrier + "cyclodextrin + surfactant" can achieve rapid and complete dissolution, while the same effect cannot be achieved when any excipient is missing or when only a single carrier is used. This proves the necessity of the excipient combination of the present invention.

[0092] Test Example 2: Stability Experiment

[0093] 1. Accelerated testing

[0094] (1) Experimental design

[0095] Acceleration conditions: 40℃±2℃, relative humidity (RH) 75%±5%, storage for 6 months.

[0096] Samples: Tablets prepared in Examples 1-3 and Comparative Examples 1-3.

[0097] Samples were taken at 0, 1, 3, and 6 months to determine the total amount of impurities in the drug and to assess the trend of impurity level changes.

[0098] (2) Experimental data and results

[0099] Table 2 Accelerated Test Results

[0100]

[0101] (3) Data Analysis

[0102] The tablets prepared in Examples 1-3 (compound carrier) and Comparative Example 1 (conventional formulation) showed essentially no change in stability during the accelerated testing period of 6 months, with the total impurities at each time point being completely consistent with those at 0 months, and no increase in impurities. However, the tablets prepared in Comparative Examples 2-3 (single carrier) showed significantly poorer stability, with the total impurities continuously increasing with storage time, reaching 3.5% to 3.7% after 6 months.

[0103] The above experimental results demonstrate that the compound carrier of the present invention can effectively solve the stability defects of single carriers and achieve long-term stability of the formulation.

[0104] 2. Long-term testing

[0105] (1) Experimental design

[0106] Storage environment: 25℃±2℃, relative humidity (RH) 60%±5% (compliant with ICH Q1A(R2) guidelines).

[0107] Samples: Tablets prepared in Examples 1-3 and Comparative Examples 1-6.

[0108] Sampling time points: 0, 3, 6, 9, and 12 months.

[0109] Detection indicators: total impurities (HPLC method), active pharmaceutical ingredient content (HPLC method), dissolution rate at 45 min (same experimental conditions as in test example 1).

[0110] (2) Experimental data and results

[0111] Table 3 Long-term test results

[0112]

[0113] (3) Data Analysis

[0114] The tablets prepared in Examples 1-3 maintained stable total impurities of 0.06%–0.10% and active pharmaceutical ingredient (API) content ≥98.5% during 12 months of long-term storage, with a dissolution rate decrease of ≤1.5%, demonstrating excellent stability. In contrast, samples with a single carrier (Comparative Examples 2-3) and those lacking excipients (Comparative Examples 4-6) all exhibited increased impurities, API degradation, and decreased dissolution rate.

[0115] The above experimental results demonstrate the stability advantage of the system of the present invention.

[0116] 3. Qualitative analysis of related substances (degradation products) (HPLC method)

[0117] (1) Experimental design

[0118] Chromatographic column: C18 column (250 mm × 4.6 mm, 5 μm);

[0119] Mobile phase: Acetonitrile-0.1% phosphoric acid aqueous solution (40:60, v / v);

[0120] Detection wavelengths: valsartan 230 nm, hydrochlorothiazide 272 nm;

[0121] Flow rate: 1.0 mL / min;

[0122] Injection volume: 20 μL;

[0123] Reference standards: valsartan reference standard (purity 99.9%), hydrochlorothiazide reference standard (purity 99.8%), known degradation impurities (purity > 98%).

[0124] Samples: Tablets prepared in Example 2 and Comparative Example 3.

[0125] (2) Experimental results and data analysis

[0126] like Figure 2 , 3 As shown, the tablets prepared in Example 2 were stored for 0 months under long-term test conditions (…). Figure 2 ) and stored for 12 months ( Figure 3 Compared to the previous example, the two spectra completely overlapped, and the peak areas of valsartan (tR≈7.2 min) and hydrochlorothiazide (tR≈4.3 min) remained unchanged; no new chromatographic peaks were added (detection limit 0.005%); and the peak area of ​​the known impurity peak (tR≈5.5 min) was <0.05%. This indicates that no new impurities were generated after long-term storage in Example 2, and the known impurities did not increase.

[0127] like Figure 3 , 4 As shown, the tablets prepared in Example 2 were stored for 12 months under long-term test conditions. Figure 3 The tablets prepared in Comparative Example 3 were placed under accelerated test conditions for 6 months. Figure 4 In comparison, the sample in Comparative Example 3 showed two new peaks (tR = 3.661 min, 6.944 min), with peak areas ranging from 0.85% to 1.20%; the sample in Example 2 did not show any of these new peaks. This indicates that a single HPMCAS carrier can generate new impurities, while the compound system of the present invention can suppress this phenomenon.

[0128] like Figure 3 , 5 As shown, the tablets prepared in Example 2 were stored for 12 months under long-term test conditions. Figure 3 ) and reference solution ( Figure 5 In contrast, the sample in Example 2 contained only valsartan, hydrochlorothiazide, and known impurity peaks, with no excipient interference peaks (no response from HPMCAS, EC, etc.). This indicates that the excipients and the drug do not interact in the system of the present invention, and there are no excipient degradation products.

[0129] The above experimental results demonstrate that the formulation of the present invention does not generate new degradation impurities during long-term storage, and its safety and stability meet the requirements for drug marketing.

[0130] Test Example 3: Bioavailability Clinical Trial

[0131] 1. Experimental Design

[0132] (1) Volunteers: 24 healthy volunteers (12 males and 12 females, aged 20-40 years, body mass index 18.5-24.9 kg / m²). 2 ).

[0133] (2) Experimental design: randomized, open, two-period crossover experiment (washing period of 7 days).

[0134] (3) Formulation

[0135] Test formulation: Valsartan / hydrochlorothiazide tablets prepared in Example 2 (specification: valsartan 80 mg / hydrochlorothiazide 12.5 mg);

[0136] Reference preparation: a conventional tablet (same specification) prepared in Comparative Example 1.

[0137] (4) Dosage regimen: After fasting for 12 hours, volunteers were given a single oral dose of 1 tablet, taken with 200 mL of warm water.

[0138] (5) Detection indicators

[0139] Five mL of venous blood were collected before administration (0 h) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h after administration. Plasma was separated by centrifugation, and the drug concentration in plasma was determined by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS / MS). Pharmacokinetic parameters (AUC) were calculated. 0-24 C max ).

[0140] 2. Experimental Data and Results

[0141] Table 4 Results of Bioavailability Experiment

[0142]

[0143] 3. Data Analysis

[0144] The test formulation (Example 2) showed relative bioavailability of over 160% for both valsartan and hydrochlorothiazide, an improvement of over 60% compared to the conventional formulation (Comparative Example 1), and C max The significantly higher levels demonstrate that the drug is absorbed at a faster rate and has higher bioavailability.

[0145] Based on the stability test results of Test Example 2, it is demonstrated that the formulation of the present invention can achieve long-term stability while ensuring high bioavailability.

[0146] The embodiments described above are only some, not all, of the embodiments of the present invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the claimed invention, but merely to illustrate selected embodiments. The scope of protection of the present invention is determined by the scope claimed in the claims. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without inventive effort are within the scope of protection of the present invention.

Claims

1. A valsartan / hydrochlorothiazide solid dispersion tablet with high bioavailability, characterized in that, The product is composed of the following raw materials in parts by weight: 10-16 parts valsartan, 1-2 parts hydrochlorothiazide, 10-16 parts solid dispersion carrier, 3-5 parts cosolvent, 1-3 parts surfactant, 4-6 parts cyclodextrin and its derivatives, and pharmaceutically acceptable excipients; wherein the solid dispersion carrier is a compound of hydroxypropyl methylcellulose acetate succinate and ethylcellulose, and the compound is used to synergistically improve the dissolution rate of valsartan and the chemical stability of the formulation; The co-solvent is at least one of polyethylene glycol 4000 and mannitol; The surfactant is at least one of Tween 80 and sodium dodecyl sulfate; The cyclodextrin and its derivatives are at least one of β-cyclodextrin and hydroxypropyl-β-cyclodextrin; The pharmaceutically acceptable excipients include fillers and lubricants; the filler is microcrystalline cellulose, and the lubricant is magnesium stearate; The method for preparing the solid dispersion tablet includes the following steps: Step 1) Weigh out the prescribed amounts of valsartan, hydrochlorothiazide, hydroxypropyl methylcellulose acetate succinate, and ethylcellulose, add them to an organic solvent, and stir in a water bath at 60-70°C until completely dissolved to form a drug-carrier solution. Step 2) Add solubilizer, surfactant and cyclodextrin and its derivatives to the drug-carrier solution obtained in Step 1), and continue stirring for 30-40 min to form a homogeneous mixture; Step 3) Spray dry the mixture obtained in step 2) and collect the solid dispersion powder; Step 4) Add pharmaceutically acceptable excipients to the solid dispersion powder obtained in step 3), mix well, and then compress into tablets to obtain the final product.

2. The valsartan / hydrochlorothiazide solid dispersion tablet with high bioavailability according to claim 1, characterized in that, The mass ratio of hydroxypropyl methylcellulose acetate succinate to ethyl cellulose is (3~4):

1.

3. A method for preparing a high-bioavailability valsartan / hydrochlorothiazide solid dispersion tablet as described in claim 1 or 2, characterized in that, Includes the following steps: Step 1) Weigh out the prescribed amounts of valsartan, hydrochlorothiazide, hydroxypropyl methylcellulose acetate succinate, and ethylcellulose, add them to an organic solvent, and stir in a water bath at 60-70°C until completely dissolved to form a drug-carrier solution. Step 2) Add solubilizer, surfactant and cyclodextrin and its derivatives to the drug-carrier solution obtained in Step 1), and continue stirring for 30-40 min to form a homogeneous mixture; Step 3) Spray dry the mixture obtained in step 2) and collect the solid dispersion powder; Step 4) Add pharmaceutically acceptable excipients to the solid dispersion powder obtained in step 3), mix well, and then compress into tablets to obtain the final product.

4. The preparation method according to claim 3, characterized in that, Step 1) The organic solvent is an ethanol-acetone mixed solvent.

5. The preparation method according to claim 3, characterized in that, Step 3) The inlet air temperature of the spray dryer is 160~180℃ and the outlet air temperature is 80~90℃.

6. The use of the tablet as described in claim 1 or 2, or the tablet prepared by any one of claims 3-5, in the preparation of a medicament for treating hypertension.

Citation Information

Patent Citations

  • Compound dispersible tablet for treating hypertension

    CN1732952A

  • Novel solid dosage forms of valsartan and hydrochlorothiazide

    WO2007049291A1